Signal from the log
Circle Pharma
92,5 M$ · Series D and later · United States · Biotech
Circle Pharma fabrique des macrocycles, de grosses molécules avalables, pour atteindre des cibles que les médicaments classiques n'attrapent pas. Son candidat CID-165 vise la cycline D1 dans le cancer du sein hormonodépendant et doit entrer en clinique début 2027.
Verified
Announced on , logged by the watch of 16 September 2026.
- Operation
- Funding round
- Announced amount
- 92,5 M$
- Stage
- Series D and later
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by The Column Group , with Nextech Invest , RA Capital Management , Euclidean Capital , Eli Lilly and Company
Provenance
Source businesswire,pulse2
Logged on 16 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.